<DOC>
	<DOCNO>NCT02698241</DOCNO>
	<brief_summary>The INTERVENE-HF study prospective , non-randomized , multi-center ( US ) , investigational , feasibility study . The purpose study characterize safety manage heart failure patient integrated device diagnostics implant commercially available Medtronic cardiac resynchronization therapy defibrillator ( CRT-D ) .</brief_summary>
	<brief_title>Integrated Diagnostics Driven Diuretic Chronic Medication Management Heart Failure</brief_title>
	<detailed_description>The study expect conducted 20 center locate United States . Up 400 subject enrol yield 200 eligible subject meet screen criterion . This study conduct subject implant , commercially available , Medtronic , CRT-D device . Each enrol subject follow every 2 month time enrollment end study.The study end last enrolled subject complete 12-month follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<criteria>Subject ( subject 's legally authorize representative ) willing able provide write informed consent . Subject wireless Medtronic CRTD device implant &gt; 9 month Medtronic lead . Subject &gt; 1 year life expectancy . Subject 's CRTD device least 18 month device longevity leave . Subject estimate Glomerular Filtration Rate ( eGFR ) &gt; 25 ml/min/1.73 m2 ( calculate within last 6 month prior enrollment ) . Subject NYHA Class II III . Subject elevate BNP value ( BNP &gt; 400 NTpro BNP &gt; 800 ) within last 3 month OR Subject Heart Failure event within last 9 month . Subjects currently prescribe take medication management heart failure able tolerate transient increase diuretic dosage . Subject willing able comply protocol protocol visit . Subject send device transmission . Subject systolic BP &lt; 90 mmHg time enrollment . Subject responsive diuretic therapy chronic renal dialysis . Subject unable tolerate change medication without safety check . Subject K+ value &lt; 3.5 mmol/L &gt; 5.5 mmol/L ( document within last 6 month prior enrollment ) . Subject Na+ value &lt; 130 mmol/L ( document within last 6 month prior enrollment ) . Subject hemoglobin value &lt; 9.0 g/dl ( document within last 6 month prior enrollment ) . Subjects enrol concurrent study may confound result study without documented preapproval Medtronic study manager . Subject weigh 500 pound . Subject young 18 year age . Subject hemodynamic monitoring device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cardiac Resynchronization Therapy Defibrillator ( CRT-D )</keyword>
	<keyword>heart failure</keyword>
	<keyword>integrate diagnostics</keyword>
	<keyword>chronic medication management</keyword>
</DOC>